FUNCTIONS OF CYCLIN D1 IN BREAST CANCER
CYCLIN D1 在乳腺癌中的功能
基本信息
- 批准号:2009080
- 负责人:
- 金额:$ 20.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-04-01 至 2002-01-31
- 项目状态:已结题
- 来源:
- 关键词:3T3 cells adenocarcinoma apoptosis breast neoplasms cell cycle cell growth regulation cell proliferation cyclins gene expression gene targeting genetic regulation genetic regulatory element genetically modified animals laboratory mouse mammary epithelium messenger RNA molecular cloning mouse mammary tumor virus natural gene amplification neoplasm /cancer genetics neoplastic transformation oncogenes polymerase chain reaction protein kinase protein metabolism protein transport tissue /cell culture
项目摘要
Physical associations between cyclins, viral oncogenes, and tumor
suppressor genes imply a central role for cyclins in growth control.
Cyclin D1 was identified as a candidate oncogene in tumor-specific
DNA rearrangements. By virtue of DNA amplification, it contributes
to 15% of breast cancers. Cyclin D1 protein is overexpressed in an
additional 15-20% of breast cancers through unknown mechanisms. To
evaluate its oncogenic potential, we overexpressed cyclin D1 in
mammary cells in transgenic mice. Overexpression resulted in
abnormal mammary proliferation and adenocarcinomas. We propose
further studies of cyclin D1's role in breast cancer: AIM 1:
Characterization of mechanisms regulating cyclin D1. Cyclin D1
protein is specifically increased in one-third of mammary carcinomas
without accompanying increases in mRNA. We will evaluate
mechanisms by which this increase in cyclin D1 protein might be
regulated using tissue culture models, and we will identify factors
regulating cyclin D1 during mammary growth and involution in vivo.
AIM 2: Characterization of growth abnormalities in mammary
epithelium overexpressing cyclin D1. The functions of cyclin D1 may
be more complex than anticipated in vivo since our new preliminary
data suggest that cyclin D1 may regulate apoptosis during mammary
involution. We will further characterize this new phenotype. We will
evaluate interactions between the genes involved in cyclin/cdk 4
complexes that might alter the role of cyclin D1 during mammary
involution. By quantifying histologic changes, we will assess the overall
function of cyclin D1 in mammary growth and involution. AIM 3:
Assessment of second oncogenic events in adenocarcinomas in
MMTV-cyclin D1 transcienic mice. Given the prolonged latency
period of tumor development in cyclin D1 transgenic mice, the role of
"second hits" will be tested by random insertional mutagenesis using
mouse mammary tumor virus infections and using differential display
of mRNAs expressed at different levels during malignant
transformation. Characterization of MMTV insertion sites by inverse
PCR and identification of differentially expressed genes during cyclin
D1-driven oncogenesis will be used to identify and clone oncogenes
that may collaborate with cyclin D1 to cause breast cancer.
细胞周期蛋白、病毒癌基因与肿瘤的物理联系
抑制基因暗示了细胞周期蛋白在生长控制中的核心作用。
细胞周期蛋白D1被认为是肿瘤特异性的候选癌基因
DNA重排。通过DNA扩增,它有助于
到15%的乳腺癌患者。Cyclin D1蛋白在人卵巢癌中的过度表达
另外15%-20%的乳腺癌是通过未知的机制发生的。至
评估其致癌潜力,我们过表达了细胞周期蛋白D1
转基因小鼠的乳腺细胞。过度表达导致
乳腺异常增殖和腺癌。我们建议
细胞周期蛋白D1‘S在乳腺癌中作用的进一步研究:目的1:
细胞周期蛋白D1调控机制的表征。细胞周期蛋白D1
蛋白质在三分之一的乳腺癌中特异性增加
而不伴随mRNA的增加。我们将评估
Cyclin D1蛋白表达增加的机制可能是
使用组织培养模型进行调控,我们将确定影响因素
乳腺生长发育和退化过程中细胞周期蛋白D1的调节。
目标2:乳腺生长异常的特征
上皮细胞过度表达细胞周期蛋白D1。细胞周期蛋白D1的功能可能
在活体内比预期的更复杂,因为我们新的初步
有数据表明,细胞周期蛋白D1可能调节乳腺细胞的凋亡
内卷曲。我们将进一步描述这种新的表型。我们会
评价细胞周期蛋白/细胞周期蛋白4相关基因之间的相互作用
可能改变细胞周期蛋白D1在乳腺过程中作用的复合体
内卷曲。通过量化组织学变化,我们将评估总体
细胞周期蛋白D1在乳腺生长发育和退化中的作用目标3:
年腺癌第二次致癌事件的评估
MMTV-Cyclin D1转基因小鼠。考虑到延长的延迟
细胞周期蛋白D_1转基因小鼠肿瘤发生发展期的作用
“第二次命中”将通过随机插入突变进行测试,
小鼠乳腺肿瘤病毒感染与差异显示技术研究
不同水平的mRNAs在癌变过程中的表达
转型。MMTV插入位点的逆序表征
周期调控基因的聚合酶链式反应及差异表达基因的筛选
将利用d1驱动的致癌作用来鉴定和克隆癌基因
这可能与细胞周期蛋白D1共同导致乳腺癌。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
EMMETT Vance SCHMIDT其他文献
EMMETT Vance SCHMIDT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('EMMETT Vance SCHMIDT', 18)}}的其他基金
Evolutionary lead optimization for immunotherapy of Marburg & Ebola viruses
马尔堡病毒免疫疗法的进化先导优化
- 批准号:
7677956 - 财政年份:2006
- 资助金额:
$ 20.61万 - 项目类别:
Evolutionary lead optimization for immunotherapy of Marburg & Ebola viruses
马尔堡病毒免疫疗法的进化先导优化
- 批准号:
7282079 - 财政年份:2006
- 资助金额:
$ 20.61万 - 项目类别:
Evolutionary lead optimization for immunotherapy of Marburg & Ebola viruses
马尔堡病毒免疫治疗的进化先导优化
- 批准号:
7133899 - 财政年份:2006
- 资助金额:
$ 20.61万 - 项目类别:
Evolutionary lead optimization for immunotherapy of Marburg & Ebola viruses
马尔堡病毒免疫疗法的进化先导优化
- 批准号:
7489458 - 财政年份:2006
- 资助金额:
$ 20.61万 - 项目类别:
HEPATITIS C TRANSGENIC MICE AS MODEL OF LIVER INJURY
丙型肝炎转基因小鼠作为肝损伤模型
- 批准号:
6170551 - 财政年份:1998
- 资助金额:
$ 20.61万 - 项目类别:
HEPATITIS C TRANSGENIC MICE AS MODEL OF LIVER INJURY
丙型肝炎转基因小鼠作为肝损伤模型
- 批准号:
2679055 - 财政年份:1998
- 资助金额:
$ 20.61万 - 项目类别:
HEPATITIS C TRANSGENIC MICE AS MODEL OF LIVER INJURY
丙型肝炎转基因小鼠作为肝损伤模型
- 批准号:
2887802 - 财政年份:1998
- 资助金额:
$ 20.61万 - 项目类别:
相似国自然基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
- 批准号:30840003
- 批准年份:2008
- 资助金额:12.0 万元
- 项目类别:专项基金项目
相似海外基金
Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
- 批准号:
478914 - 财政年份:2023
- 资助金额:
$ 20.61万 - 项目类别:
Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
- 批准号:
23K14913 - 财政年份:2023
- 资助金额:
$ 20.61万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
- 批准号:
23K15035 - 财政年份:2023
- 资助金额:
$ 20.61万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
- 批准号:
10442874 - 财政年份:2023
- 资助金额:
$ 20.61万 - 项目类别:
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
- 批准号:
10657069 - 财政年份:2023
- 资助金额:
$ 20.61万 - 项目类别:
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
- 批准号:
23K08326 - 财政年份:2023
- 资助金额:
$ 20.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
- 批准号:
23K14614 - 财政年份:2023
- 资助金额:
$ 20.61万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
- 批准号:
23K15075 - 财政年份:2023
- 资助金额:
$ 20.61万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
- 批准号:
23H02698 - 财政年份:2023
- 资助金额:
$ 20.61万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
- 批准号:
10743611 - 财政年份:2023
- 资助金额:
$ 20.61万 - 项目类别: